Making the Case for All-Oral, Shorter Regimens for Children with Drug-Resistant Tuberculosis

The past decade has witnessed a transformation in the treatment of rifampicin-resistant/multidrug-resistant (RR/MDR) tuberculosis (TB), with a four-drug, 6-month regimen supported by high-quality evidence now being recommended for most adults. Children (

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of respiratory and critical care medicine 2023-07, Vol.208 (2), p.130-131
Hauptverfasser:	Patankar, Sayalee, Cruz, Andrea T, Douglas-Jones, Bianca, Garcia-Prats, Anthony, Kay, Alexander, Reuter, Anja, Schaaf, H Simon, Seddon, James A, Sharma, Sangeeta, Starke, Jeffrey, Tommasi, Marcela, Triasih, Rina, Furin, Jennifer J
Format:	Artikel
Sprache:	eng
Schlagworte:	Antitubercular Agents - therapeutic use Child Children & youth Clinical Protocols Clinical trials Drug resistance Humans Medical treatment Multidrug resistant organisms Pediatrics Tuberculosis Tuberculosis, Multidrug-Resistant - drug therapy Viewpoint: Turning the Air Blue
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The past decade has witnessed a transformation in the treatment of rifampicin-resistant/multidrug-resistant (RR/MDR) tuberculosis (TB), with a four-drug, 6-month regimen supported by high-quality evidence now being recommended for most adults. Children (
ISSN:	1073-449X 1535-4970
DOI:	10.1164/rccm.202304-0670VP